Important to note is that anti-angiogenic immunotherapy in the form of anti-VEGF plus anti-PDL1 induced the noncanonical LTβR pathway in ECs of breast and pancreatic endocrine tumors, which enabled HEV formation, enhanced lymphocyte infiltration, and prolonged survival of tumor-bearing mice (113). This evidence concerns the gene LTBR and pancreatic neuroendocrine tumor.